Medical

K-Drug Approved For Adjuvant Treatment Of Early-Stage Non-Small Cell Lung Cancer, Significantly Extending Cancer-Free Survival Of Patients!

The US FDA has approved pablizumab (Keytruda) as an adjuvant treatment for early-stage non-small cell lung cancer. In the trial, pablizumab (Keytruda) significantly prolonged cancer-free survival in patients compared to placebo.

Medical

BEA-17 Granted Orphan Drug Designation By FDA For The Treatment Of Glioblastoma

Data from a study recently published by the Royal Marsden Cancer Centre showed promising data for the combination of Avutometinib + Defactinib in the treatment of ovarian cancer, resulting in significant tumour shrinkage in 28% of patients and disease control in 93% of patients.